SPYRE THERAPEUTICS, INC. Basic Shares Outstanding (Weighted Average)
SPYRE THERAPEUTICS, INC. (SYRE) reported Basic Shares Outstanding (Weighted Average) of 50.89 million shares for the 3-month period ending 2024-09-30, per its 10-Q/A filed 2024-11-18.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2024-11-18
- SPYRE THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2024-09-30 was 50.89M shares, a 1085.18% increase year-over-year.
- SPYRE THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2024-06-30 was 45.32M shares, a 1085.48% increase year-over-year.
- SPYRE THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2024-03-31 was 36.51M shares, a 868.38% increase year-over-year.
- SPYRE THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2023-12-31 was 15.70M shares, a 311.52% increase year-over-year.
- SPYRE THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2023 was 6.90M shares, a 104.59% increase from fiscal 2022.
- SPYRE THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2022 was 3.37M shares, a 28.19% increase from fiscal 2021.
- SPYRE THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2021 was 2.63M shares, a 95.07% decline from fiscal 2020.
- SPYRE THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2020 was 53.37M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 6 month as first filed | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 9 month as first filed | Weighted Average Number of Shares Outstanding, Basic 12 month | Weighted Average Number of Shares Outstanding, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 50.89M shares 10-Q/A · filed 2024-11-18 | 48.10M shares derived: average of 2 quarters · filed 2024-11-18 | 44.26M shares 10-Q/A · filed 2024-11-18 | 37.11M shares derived: average of 4 quarters · filed 2024-11-18 | ||||
| 2024-06-30 | 45.32M shares 10-Q/A · filed 2024-11-18 | 40.91M shares 10-Q/A · filed 2024-11-18 | 32.51M shares derived: average of 3 quarters · filed 2024-11-18 | 25.46M shares derived: average of 4 quarters · filed 2024-11-18 | ||||
| 2024-03-31 | 36.51M shares 10-Q/A · filed 2024-11-18 | 26.11M shares derived: average of 2 quarters · filed 2024-11-18 | 18.84M shares derived: average of 3 quarters · filed 2024-11-18 | 15.08M shares derived: average of 4 quarters · filed 2024-11-18 | ||||
| 2023-12-31 | 15.70M shares derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2024-11-18 | 10.00M shares derived: average of 2 quarters · filed 2024-11-18 | 7.94M shares derived: average of 3 quarters · filed 2024-11-18 | 6.90M shares 10-K/A · filed 2024-11-18 | ||||
| 2023-09-30 | 4.29M shares 10-Q/A · filed 2024-11-18 | 4.06M shares derived: average of 2 quarters · filed 2024-11-18 | 3.96M shares 10-Q/A · filed 2024-11-18 | 3.93M shares derived: average of 4 quarters · filed 2024-11-18 | ||||
| 2023-06-30 | 3.82M shares 10-Q/A · filed 2024-11-18 | 95.57M shares 10-Q · filed 2023-08-11 | 3.80M shares 10-Q/A · filed 2024-11-18 | 94.92M shares 10-Q · filed 2023-08-11 | 3.80M shares derived: average of 3 quarters · filed 2024-11-18 | 3.79M shares derived: average of 4 quarters · filed 2024-11-18 | ||
| 2023-03-31 | 3.77M shares 10-Q/A · filed 2024-11-18 | 94.26M shares 10-Q · filed 2023-05-11 | 3.79M shares derived: average of 2 quarters · filed 2024-11-18 | 3.78M shares derived: average of 3 quarters · filed 2024-11-18 | 23.39M shares derived: average of 4 quarters · filed 2024-11-18 | |||
| 2022-12-31 | 3.82M shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18 | 3.79M shares derived: average of 2 quarters · filed 2024-11-18 | 29.93M shares derived: average of 3 quarters · filed 2024-11-18 | 3.37M shares 10-K/A · filed 2024-11-18 | 84.28M shares 10-K · filed 2023-03-02 | |||
| 2022-09-30 | 3.77M shares 10-Q · filed 2023-11-09 | 94.20M shares 10-Q · filed 2022-11-03 | 42.99M shares derived: average of 2 quarters · filed 2023-11-09 | 3.22M shares 10-Q · filed 2023-11-09 | 80.57M shares 10-Q · filed 2022-11-03 | -8.63M shares derived: average of 4 quarters · filed 2024-11-18 | ||
| 2022-06-30 | 82.21M shares 10-Q · filed 2023-08-11 | 73.65M shares 10-Q · filed 2023-08-11 | -12.77M shares derived: average of 3 quarters · filed 2024-11-18 | 6.87M shares derived: average of 4 quarters · filed 2024-11-18 | ||||
| 2022-03-31 | 66.00M shares 10-Q · filed 2023-05-11 | -60.26M shares derived: average of 2 quarters · filed 2024-11-18 | -18.24M shares derived: average of 3 quarters · filed 2024-11-18 | 2.73M shares derived: average of 4 quarters · filed 2024-11-18 | ||||
| 2021-12-31 | -186.51M shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18 | -60.36M shares derived: average of 2 quarters · filed 2024-11-18 | -18.36M shares derived: average of 3 quarters · filed 2024-11-18 | 2.63M shares 10-K/A · filed 2024-11-18 | 65.74M shares 10-K · filed 2023-03-02 | |||
| 2021-09-30 | 65.79M shares 10-Q · filed 2022-11-03 | 65.71M shares derived: average of 2 quarters · filed 2022-11-03 | 65.68M shares 10-Q · filed 2022-11-03 | |||||
| 2021-06-30 | 65.63M shares 10-Q · filed 2022-08-04 | 65.62M shares 10-Q · filed 2022-08-04 | ||||||
| 2020-12-31 | 53.37M shares 10-K · filed 2023-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |